Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus CAPOX for unresectable high-risk locally advanced rectal cancer (pMMR/MSS)
ChiCTR2600129426Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in rectal cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Complete Response Rate (pCR + cCR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2600129426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129426.